Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP-LGG 2004 study for children and adolescents with low grade glioma
NL-OMON20306Active, not recruiting
- Sponsor
- International: SIOP De voorzitter van de Trial Management Committee: Dr. Astrid K. Gnekow I. Klinik fuer Kinder und Jugendliche, Klinikum Augsburg Stenglinstrasse.4 D-86156 Augsburg, Germany National: Dutch Childhood Oncology Group (DCOG)
- Start
- May 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vincristine, carboplatin and etoposide in low-grade glioma (LGG) (2 arms), sponsored by International: SIOP De voorzitter van de Trial Management Committee: Dr. Astrid K. Gnekow I. Klinik fuer Kinder und Jugendliche, Klinikum Augsburg Stenglinstrasse.4 D-86156 Augsburg, Germany National: Dutch Childhood Oncology Group (DCOG). Primary endpoint: Progression-free survival. Started May 2008; status: active, not recruiting.
02
Drugs
vincristinecarboplatinetoposide
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NL-OMON20306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20306.